# Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

> **NCT03523975** · PHASE1,PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 28 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03523975
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-12-24
- **Primary completion:** 2027-06-24
- **Final completion:** 2027-06-24
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523975, "Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03523975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*